Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares rose 3.1% during mid-day trading on Monday . The stock traded as high as $101.80 and last traded at $101.02, with a volume of 779,024 shares traded. The stock had previously closed at $98.01.

VRTX has been the subject of several analyst reports. Jefferies Group reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 31st. Vetr lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $94.05 target price for the company. in a research report on Monday, May 23rd. Morgan Stanley reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, May 12th. Leerink Swann reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Thursday, April 28th. Finally, Robert W. Baird reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Monday, April 25th. Nine research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $120.43.

The company’s market cap is $24.94 billion. The company has a 50 day moving average price of $95.19 and a 200-day moving average price of $88.19.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.03. The company earned $431.61 million during the quarter, compared to the consensus estimate of $428.08 million. Vertex Pharmaceuticals’s quarterly revenue was up 159.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.54) earnings per share. Equities analysts expect that Vertex Pharmaceuticals Incorporated will post $1.04 earnings per share for the current fiscal year.

In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 900 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The shares were sold at an average price of $100.19, for a total transaction of $90,171.00. Following the completion of the transaction, the director now owns 268,225 shares of the company’s stock, valued at $26,873,462.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Joshua S. Boger sold 6,900 shares of the firm’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $99.63, for a total transaction of $687,447.00. Following the transaction, the director now directly owns 274,725 shares of the company’s stock, valued at approximately $27,370,851.75. The disclosure for this sale can be found here.

Several institutional investors have made changes to their positions in the stock. Calvert Investment Management Inc. increased its position in shares of Vertex Pharmaceuticals by 30.0% in the fourth quarter. Calvert Investment Management Inc. now owns 11,843 shares of the pharmaceutical company’s stock worth $1,490,000 after buying an additional 2,734 shares in the last quarter. KBC Group NV increased its position in shares of Vertex Pharmaceuticals by 53.0% in the fourth quarter. KBC Group NV now owns 42,623 shares of the pharmaceutical company’s stock worth $5,363,000 after buying an additional 14,759 shares in the last quarter. Nicholas Co. Inc. WI increased its position in shares of Vertex Pharmaceuticals by 4.8% in the fourth quarter. Nicholas Co. Inc. WI now owns 44,035 shares of the pharmaceutical company’s stock worth $5,540,000 after buying an additional 2,000 shares in the last quarter. American International Group Inc. increased its position in shares of Vertex Pharmaceuticals by 2.0% in the fourth quarter. American International Group Inc. now owns 110,088 shares of the pharmaceutical company’s stock worth $13,852,000 after buying an additional 2,175 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Vertex Pharmaceuticals by 5.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 625,112 shares of the pharmaceutical company’s stock worth $78,658,000 after buying an additional 33,936 shares in the last quarter.

Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.